Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 6/20 | 0.54 |
| ▸ | CRBN | Q96SW2 | 6/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30066453 | 1.00 | DDB1 (0.54) | DDB1CRBNHRH3GPR119CNR1 | |
| SCHEMBL24671737 | 0.89 | DDB1 (0.54) | DDB1CRBNGPR119CNR1BACE1 | |
| SCHEMBL29751197 | 0.89 | CRBN (0.60) | DDB1CRBNHRH3GPR119MAP4K4 | |
| SCHEMBL24607627 | 0.89 | CRBN (0.60) | DDB1CRBNHRH3GPR119MAP4K4 | |
| SCHEMBL24671676 | 0.86 | DDB1 (0.50) | DDB1CRBNGPR119CNR1 | |
| SCHEMBL30066372 | 0.86 | DDB1 (0.50) | DDB1CRBNGPR119CNR1 | |
| SCHEMBL27161752 | 0.86 | DDB1 (0.54) | DDB1CRBNGPR119CNR1BACE1 | |
| SCHEMBL30289184 | 0.85 | DRD2 (0.51) | DDB1CRBNMAP4K4 | |
| SCHEMBL24480913 | 0.83 | GPR119 (0.56) | DDB1CRBNGPR119BACE1 | |
| SCHEMBL25420011 | 0.82 | CRBN (0.47) | DDB1CRBNHRH3GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279202-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| WO-2022235715-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279202-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | ITK, NFATC1, TNIK | DDB1 2514/4885CRBN 929/4885HRH3 2838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.